Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CBD Biotechnology is a Shanghai-based biotechnology company specializing in the research, development, and commercialization of cannabidiol (CBD)-infused health and skincare products. Established in 2017, the company was a pioneer in the Chinese market, integrating hemp-derived CBD into high-end cosmetics and wellness solutions. Its product portfolio features the "CBD Magic Hemp Series" and "Live Oxygen Series," which leverage the antioxidant and anti-inflammatory properties of cannabinoids to address skin aging, acne, and moisturizing needs. The company operates through a vertically integrated model, from scientific innovation in hemp extraction to distribution via major e-commerce platforms like Tmall and Taobao. Despite the restructuring of its original parent company, CBD Biotechnology remains a key player in the Asian industrial hemp sector, focusing on regulatory compliance and consumer-driven wellness innovation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CBD Biotechnology.